Targeting the CDK4/6 pathway through treatment with CDK4/6 inhibitors in combination with letrozole has led to significant improvement in progression-free survival (PFS) compared with that achieved with single-agent ET in first-line HR+ breast cancer [7, 8]. This evidence concerns the gene CDK4 and breast carcinoma.